期待一下

现在才看到这个。我发现我雪球名字有好几个近似的，很容易弄混。
这只在观察池里，靠谱的小公司。2024-04-23 FDA accelerated 批准，还获得一张儿科罕见病优先评审券（价值$1亿？）。接下来得看至少两个季度的销售如何、从而决定被收购的价格吧（如果有收购的话）？
兄台另外还关注哪些？
==2024-04-23
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved OJEMDA (tovorafenib), a type II RAF inhibitor, for the treatment of patients 6 months of age and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response. With the approval, Day One received a rare pediatric disease priority review voucher from the FDA.